Reach Us +44-3308187254


Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Agomelatine And Its Reproduction Effects | 50298
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Agomelatine and its reproduction effects

7th Annual Global Pharma Summit

Haluk Kelestimur

Firat University, Turkey

ScientificTracks Abstracts: Clin Pharmacol Biopharm

DOI: 10.4172/2167-065X.C1.019

Most of the pharmacological agents which are used in the treatment of depression are known to disrupt normal sexual function, which affects the patient’s quality of life and represents the main side effect that leads to the discontinuation of treatment. Agomelatine has been reported not to cause sexual dysfunction requiring treatment. All dose regimens of agomelatine have been reported to be well tolerated and have no unexpected adverse event. Understanding that there is a strong interaction between circadian rhythm desynchronization and mood disorders is another reason, which has led to the development of agomelatine. Agomelatine is a melatonergic agonist for MT1 and MT2 receptors and a serotonin (5-HT)2C receptor antagonist. This compound was initially investigated as a chronobiotic; however, with the discovery of the 5-HT2C antagonist activity the emphasis shifted to its anxiolytic and antidepressant effects. The antidepressant-like activity of agomelatine has been suggested to depend on a combination of its melatonin agonist and 5-HT2C antagonist properties. There are a few studies on sexual side-effects of agomelatine in the treatment of depression in humans. Agomelatine is suggested to demonstrate favorable sexual acceptability in depressed patients and healthy volunteers and therefore to be a good option for the treatment of depression because it would not have adverse effects on sexual function. Abnormal sperm parameters have been found to be associated with treatment with the SSRI citalopram but no similar association with agomelatine. The effects of agomelatine on sexual response have not been studied sufficiently in animal models. In our study, chronic treatment with agomelatine has been found not to lead to adverse effects on sexual behavior and even exerts some putative pro-sexual effects in adult male rats. To our knowledge, this study provides the first evidence of lack of sexual dysfunction by chronic agomelatine treatment in rats. Our work also shows that agomelatine induces an antidepressant-like effect by means of enhancement of serotonergic and possible dopaminergic activity. Our studies suggest that the effects of chronic agomelatine administration on reproductive seem to be sex-dependent. Because agomelatine advanced vaginal opening in the female rats whereas it delayed puberty onset in the male rats, clinical use of agomelatine may lead to different side-effects on puberty in male and female. The understanding of the effects of agomelatine will not only contribute to the delination of the combination of melatonergic and 5-HT2C receptor activation in the treatment of depression, but may also provide new therapeutic approaches to treat some reproductive disorders.

Haluk Kelestimur has received his PhD degree in the Department of Physiology, School of Medicine at Firat University in 1986. During his Postdoctoral studies at University College London between 1988 and 1990, he studied on the interaction between pineal gland and neurohypophysis in rats. In 2007, he has participated in a project to examine the relationship between kisspeptin and melatonin using the rat as an experimental model in Pittsburg University, Department of Cell Biology and Physiology. In 2012, he has worked in a project on neuroendocrine mechanisms controlling stress-induced advancement of puberty in King’s College London. He has published about 70 scientific papers in reputed indexed international journals till date. He has been the Head of the Department of Physiology, School of Medicine at Firat University since 1997.

Email: [email protected]

Relevant Topics